COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,786 Articles (22,946 medRxiv, 8,840 bioRxiv)

Most recent first Previous |  Page 812: Articles 8111-8120  | Next

Investigating the optimum sample type and target genes for SARS-CoV-2 detection
Zhan, J., Xie, Y., Wang, J., Hang, X.
10.1101/2022.05.25.22275564 — Posted: 2022-06-02
Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study
Costa Clemens, S. A., Milan, E. P., Sprinz, E., Neto, J. C., Pacciarini, F., Li, P., Chen, H.-L., Smolenov, I., Pollard, A., Clemens, R.
10.1101/2022.05.31.22275010 — Posted: 2022-06-02
U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022
Ben Hamida, A., Charles, M., Murrill, C., Henao, O., Gallagher, K.
10.1101/2022.06.01.22275786 — Posted: 2022-06-01
Artificial intelligence tool for the study of COVID-19 microdroplet spread across the human diameter and airborne space
Alsaadi, H. H., Aldwairi, M., Yasin, F., Cachinho, S. C. P., Hussein, A.
10.1101/2022.06.01.22275872 — Posted: 2022-06-01
COVID-19 is not an Independent Cause of Death
Castro, M. C., Gurzenda, S., Turra, C. M., Kim, S., Andrasfay, T., Goldman, N.
10.1101/2022.06.01.22275878 — Posted: 2022-06-01
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha (B.1.1.7), Delta (B.1.617.2) or Omicron (B.1.1.529) dominance: A Danish nationwide study
Nielsen, K. F., Moustsen-Helms, I. R., Schelde, A. B., Gram, M. A., Emborg, H.-D., Nielsen, J., Hansen, C. H., Andersen, M. A., Meaidi, M., Wohlfahrt, J., Valentiner-Branth, P.
10.1101/2022.06.01.22275858 — Posted: 2022-06-01
Symptom variation, correlations, and relationship to physical activity in Long Covid: intensive longitudinal study
Burton, C., Dawes, H., Goodwill, S., Thelwell, M., Dalton, C.
10.1101/2022.05.31.22275746 — Posted: 2022-06-01
Severe acute respiratory syndrome coronavirus 2 breakthrough infections in healthcare workers vaccinees with BNT162b2 (Pfizer-BioNtech) in Bogota, Colombia
Tavera-Rodriguez, P., Barbosa-Ramirez, J., Bermudez-Forero, A., Prada-Cardozo, D., Reales-Gonzalez, J., Pelaez-Carvajal, D., Malo-Sanchez, D., Meneses-Gil, M.-X., Mercado-Reyes, M.
10.1101/2022.05.31.22274501 — Posted: 2022-06-01
Antiviral immune responses, cellular metabolism and adhesion are differentially modulated by SARS-CoV-2 ORF7a or ORF7b
Garcia-Garcia, T., Fernandez-Rodriguez, R., Redondo, N., de Lucas-Rius, A., Zaldivar-Lopez, S., Dies Lopez-Ayllon, B., Suarez-Cardenas, J. M., Jimenez-Marin, A., Montoya, M., Garrido, J. J.
10.1101/2022.06.01.494101 — Posted: 2022-06-01
SUMOylation of SARS-CoV-2 Nucleocapsid protein enhances its interaction affinity and plays a critical role for its nuclear translocation
Liao, J., Madahar, V., Rodgers, V. G. J.
10.1101/2022.05.31.494262 — Posted: 2022-06-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).